IDH1 and cancer: The amount of carnitine derivatives, including propionylcarnitine, is lower in IDH1 and IDH2 mutants [50,51], which can contribute to increased fatty acid synthesis, decreased oxidation of certain fatty acids, and accelerated proliferation of cancer cells and tumor growth.